Mucus Relief Extended-release

Guaifenesin


Strategic Sourcing Services Llc
Human Otc Drug
NDC 70677-0050
Mucus Relief Extended-release also known as Guaifenesin is a human otc drug labeled by 'Strategic Sourcing Services Llc'. National Drug Code (NDC) number for Mucus Relief Extended-release is 70677-0050. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Mucus Relief Extended-release drug includes Guaifenesin - 1200 mg/1 . The currest status of Mucus Relief Extended-release drug is Active.

Drug Information:

Drug NDC: 70677-0050
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Mucus Relief Extended-release
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Guaifenesin
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Strategic Sourcing Services Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:GUAIFENESIN - 1200 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 11 Jul, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 30 May, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA207342
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 15 Jan, 2025
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Strategic Sourcing Services LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:310621
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0010939907448
UPC stands for Universal Product Code.
NUI:N0000193956
N0000008867
N0000009560
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:495W7451VQ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Expectorant [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Decreased Respiratory Secretion Viscosity [PE]
Increased Respiratory Secretions [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class:Decreased Respiratory Secretion Viscosity [PE]
Expectorant [EPC]
Increased Respiratory Secretions [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
70677-0050-114 BLISTER PACK in 1 CARTON (70677-0050-1) / 1 TABLET in 1 BLISTER PACK11 Jul, 201830 May, 2025No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose expectorant

Product Elements:

Mucus relief extended-release guaifenesin guaifenesin guaifenesin silicon dioxide magnesium stearate carbomer 934 cellulose, microcrystalline povidone hypromellose, unspecified lactose monohydrate talc fd&c blue no. 1 an037

Indications and Usage:

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and makes coughs more productive.

Warnings:

Warnings do not use for children under 12 years of age. ask a doctor before use if you have persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis or emphysema cough accopanied by too much phlegm (mucus) stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash or persistent headache. these could be signs of a serious illness. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away (1-800-222-1222).

Do Not Use:

Warnings do not use for children under 12 years of age. ask a doctor before use if you have persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis or emphysema cough accopanied by too much phlegm (mucus) stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash or persistent headache. these could be signs of a serious illness. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away (1-800-222-1222).

Dosage and Administration:

Directions do not crush, chew, or break tablet take with a full glass of water this product can be administered without regard for the timing of meals adults and children 12 years of age and over: 1 tablet every 12 hours. do not exceed 2 tablets in 24 hours. children under 12 years of age: do not use

Stop Use:

Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash or persistent headache. these could be signs of a serious illness.

Package Label Principal Display Panel:

Principal display panel compare to maximum strength mucinex® active ingredient* maximum strength mucus relief 12-hour relief relieves chest congestion thins and loosen mucus expectorant guaifenesin extended-release tablets *this product is not manufactured or distributed by reckitt benckiser llc, distributor of maximum strength mucinex®. tamper evident: do not use if blister unit is torn, broken or shows any signs of tampering. keep outer carton for complete warnings and product information. another quality product distributed by mckesson one post street, san francisco, ca 94104 www.sunmarkbrand.com

Package label sunmark maximum strength mucus relief guaifenesin 1200 mg

Further Questions:

Questions or comments? call 1-877-753-3935 monday-friday 9am-5pm est


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.